Medication info
Actos 15 mg Tablets (Pioglitazone Hydrochloride)

Actos 15 mg Tablets (Pioglitazone Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Celltrion Pharm, Inc.
Appearance
White or almost white, convex cylindrical tablets
Packaging
30 tablets/PTP [10 tablets/PTP packaging X 3], 30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200108671 · Approved 2001.01.16 · Insurance code 693903510

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
This medicine is administered orally once daily, regardless of meals. The management of diabetes should be individualized for each patient. Ideally, the response to treatment should be evaluated by monitoring glycated hemoglobin (HbA1c), which is a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the previous 2 ~ 3 months. Clinically, this medicine should be administered for an adequate period to assess changes in glycated hemoglobin (at least 3 months), provided that the patient's glycemic control does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this medicine is not sufficiently effective, the dose may be increased to up to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea, with an initial dose of 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and regimen. However, if the patient develops symptoms of hypoglycemia, the dose of the sulfonylurea should be reduced. 2) Metformin: This medicine may be administered in combination with metformin, with an initial dose of 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be maintained when combination therapy with this medicine is initiated. However, in patients receiving this medicine in combination with insulin, the insulin dose may be reduced by 10 ~ 25 % if symptoms of hypoglycemia occur or plasma glucose concentrations decrease to 100 mg/dL or less. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see the Renal Impairment subsection under General Precautions). Therapy with this medicine should not be initiated if, at the start of treatment, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT at least 2.5 times the upper limit of normal) (see the Effects on the Liver subsection under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting therapy with this medicine and periodically thereafter. No data are available on the use of this medicine in combination with other thiazolidinediones.
Child dose
Use is not recommended in children under 18 years of age because there is no experience with its use.

Ingredients

Importer
Celltrion Pharm, Inc.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This drug is used to help control blood sugar levels in patients with type 2 diabetes. It is administered as an adjunct to dietary and exercise therapy and can be used alone or in combination with other medications. This helps effectively improve blood sugar levels and supports diabetes management.

How to take

Adult dose

This medicine is administered orally once daily, regardless of meals. The management of diabetes should be individualized for each patient. Ideally, the response to treatment should be evaluated by monitoring glycated hemoglobin (HbA1c), which is a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the previous 2 ~ 3 months. Clinically, this medicine should be administered for an adequate period to assess changes in glycated hemoglobin (at least 3 months), provided that the patient's glycemic control does not worsen. 1. Monotherapy This medicine may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose of this medicine is not sufficiently effective, the dose may be increased to up to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medicine may be administered in combination with a sulfonylurea, with an initial dose of 15 mg once daily. When used in combination with this medicine, the current sulfonylurea may be continued at the same dose and regimen. However, if the patient develops symptoms of hypoglycemia, the dose of the sulfonylurea should be reduced. 2) Metformin: This medicine may be administered in combination with metformin, with an initial dose of 15 mg once daily. When used in combination with this medicine, the current metformin may be continued at the same dose and regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medicine. 3) Insulin: This medicine may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be maintained when combination therapy with this medicine is initiated. However, in patients receiving this medicine in combination with insulin, the insulin dose may be reduced by 10 ~ 25 % if symptoms of hypoglycemia occur or plasma glucose concentrations decrease to 100 mg/dL or less. Subsequent dose adjustments should be individualized according to glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see the Renal Impairment subsection under General Precautions). Therapy with this medicine should not be initiated if, at the start of treatment, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT at least 2.5 times the upper limit of normal) (see the Effects on the Liver subsection under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting therapy with this medicine and periodically thereafter. No data are available on the use of this medicine in combination with other thiazolidinediones.

Child dose

Use is not recommended in children under 18 years of age because there is no experience with its use.

Precautions

This drug is used for the treatment of type 2 diabetes and only lowers blood sugar levels when insulin is present. This drug can put stress on the heart, so it should not be used in patients with congestive heart failure or a history of heart failure. During treatment, fluid retention may occur, leading to swelling and increasing the risk of worsening heart failure, so careful monitoring is necessary. If symptoms of heart failure, such as shortness of breath or swelling, occur during treatment, notify the healthcare provider immediately. This drug should not be used in patients with active bladder cancer or a history of bladder cancer, and if symptoms such as hematuria or urinary difficulties develop during treatment, inform the physician immediately. Since this drug may affect liver function, regular liver function tests should be conducted before and during treatment, and if liver dysfunction is suspected, consult a healthcare provider immediately. This drug may cause weight gain and edema, so careful management is necessary if there are changes in weight or symptoms of swelling. There is a risk of hypoglycemia, so when used in combination with insulin or other hypoglycemic agents, pay attention to symptoms of hypoglycemia, and dosage adjustments may be needed as necessary. Pregnant women or women who may become pregnant should consult a physician before taking this drug, and women of childbearing age should use appropriate contraceptive methods to prevent pregnancy. Elderly patients or those with impaired renal and liver function require closer monitoring when taking this drug. During treatment, adhere to the prescribed times and dosages, and do not double the dose the next day if a dose is missed. Regular checks of blood sugar and glycosylated hemoglobin should be performed to confirm blood sugar control. There may be drug interactions, so if taking other medications, inform the physician or pharmacist. This drug is not recommended for children as its safety and efficacy have not been established.

Side effects

Congestive heart failure, excessive and rapid weight change, shortness of breath, edema, fluid retention, edema, upper respiratory infection, headache, sinusitis, myalgia, pharyngitis, abdominal bloating, weight gain, hypoglycemia, urinary tract infection, low back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, cardiovascular-related mortality, hospitalization due to worsening congestive heart failure, emergency room visit due to congestive heart failure, cardiovascular abnormalities, liver failure, diabetic macular edema with vision loss, increased blood sugar, loss of appetite, constipation, upper abdominal pain, chest pain, fatigue, weakness, dyspepsia, nausea, shortness of breath, itching, chest discomfort, trembling, chills, gastrointestinal disease, abdominal pain, epigastric discomfort, numbness, muscle rigidity, head discomfort, elevated liver enzymes, worsening liver disease, urticaria, eczema, arthralgia, knee abnormalities, arm weakness syndrome, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simple herpes, visual disturbances, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, heart failure, fractures, bladder cancer

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a special container to protect it from light and air exposure, and should be kept away from damp places. The appropriate storage temperature is between 15 degrees and 30 degrees, and it is advisable to store it particularly around 25 degrees.

Appearance and packaging

Appearance

White or almost white, convex cylindrical tablets

Package unit

30 tablets/PTP [10 tablets/PTP packaging X 3], 30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.